Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 10Phase 1/2 6Phase 3 4Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1GATA2 Deficiency 1

Interventions

venetoclax 12Cytarabine 12Azacitidine 10Decitabine 8Daunorubicin 7Cyclophosphamide 7Busulfan 6fludarabine phosphate 5Idarubicin 5Gemtuzumab 5Thiotepa 3Stem Cell Transplantation 3Filgrastim 3Cyclosporine 3vosaroxin 2fludarabine 2Whole-Body Irradiation 2Tretinoin 2Sorafenib 2Radiotherapy 2Methylprednisolone 2Methotrexate 2Melphalan 2Injections 2Etoposide 2Cladribine 2CPX-351 2Antilymphocyte Serum 2Abatacept 2vedolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Leukemia, Myeloid, Acute × midostaurin × Clear all
NCT03092674 2025-01-16

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 2/3 Completed
76 enrolled 16 charts
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡